PG
REGN icon

Pendal Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Pendal Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$85.4M Buy
118,417
+6,651
+6% +$4.91M 0.74% 50
2022
Q3 		$77M Sell
111,766
-47,013
-30% -$29.6M 0.75% 52
2022
Q2 		$93.9M Buy
158,779
+155,795
+5,221% +$101M 0.92% 43
2022
Q1 		$2.08M Sell
2,984
-2,262
-43% -$1.43M 0.02% 247
2021
Q4 		$3.31M Buy
+5,246
New +$3.23M 0.03% 188
2021
Q3 		– Sell
-508
Closed -$284K – 642
2021
Q2 		$284K Buy
+508
New +$257K ﹤0.01% 508
2020
Q4 		– Sell
-928
Closed -$519K – 547
2020
Q3 		$519K Sell
928
-1,606
-63% -$974K 0.01% 316
2020
Q2 		$1.58M Sell
2,534
-3,859
-60% -$2.19M 0.02% 199
2020
Q1 		$3.12M Buy
6,393
+2,788
+77% +$1.15M 0.05% 125
2019
Q4 		$1.35M Buy
3,605
+3,054
+554% +$1.03M 0.02% 234
2019
Q3 		$153K Sell
551
-3,422
-86% -$1.01M ﹤0.01% 420
2019
Q2 		$1.24M Buy
+3,973
New +$1.32M 0.02% 261
2018
Q2 		– Sell
-17,852
Closed -$6.15M – 483
2018
Q1 		$6.15M Buy
17,852
+8,396
+89% +$2.92M 0.08% 154
2017
Q4 		$3.56M Buy
9,456
+9,307
+6,246% +$3.77M 0.05% 180
2017
Q3 		$66.6K Buy
+149
New +$70.9K ﹤0.01% 439

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pendal Group's REGN Position: Q4 2022 in Review

Pendal Group increased its Regeneron Pharmaceuticals (REGN) stake by 6% in Q4 2022, buying an estimated $4.91M and bringing the position to 118,417 shares worth $85.4M. The position accounts for 0.74% of the portfolio, ranked #50.

Pendal Group first reported a position in REGN in Q3 2017 and has held it in 15 quarters since. The position peaked at $93.9M in Q2 2022. 1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • Pendal Group held 118,417 shares of Regeneron Pharmaceuticals worth $85.4M as of Q4 2022.
  • Pendal Group bought 6,651 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $4.91M.
  • Regeneron Pharmaceuticals made up 0.74% of Pendal Group's portfolio in Q4 2022, its #50 holding.
  • Pendal Group first reported a position in Regeneron Pharmaceuticals in Q3 2017 and has held it in 15 quarters since.
  • Pendal Group's Regeneron Pharmaceuticals position peaked at $93.9M in Q2 2022.
  • 1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Pendal Group's 13F filing for Q4 2022, filed 19 Jan 2023.